US vaping businesses: product classification, operating roles and FDA registration
Also in Market Access
Summary: Before treating an FDA registration record as permission to sell, separate the product’s classification from the business’s actual activities. Domestic establishment registration, product listing and product-specific marketing status answer different questions.
Checked 19 November 2026. This guide covers federal classification and domestic establishment registration for consumer electronic nicotine delivery systems (ENDS). It is not an individual product determination, a drug or device filing guide, or a destination-specific permission to trade.
A business can sell finished vapes, mix e-liquids, relabel packages and import products under the same trading name. Those activities do not raise the same registration question. The useful starting point is not simply whether the business calls itself a retailer or an importer, but what the product is, what happens at each establishment, and who owns or operates it. FDA’s ENDS information and the registration statute address different parts of that assessment. U05R U02
Start with the product, not the registration form
Federal tobacco law covers products made or derived from tobacco, or containing nicotine from any source, intended for human consumption, including components, parts and accessories. The component, part and accessory wording has a carve-out for raw materials other than tobacco used to manufacture those items. It also excludes drugs, devices and combination products, and food containing no nicotine or no more than trace amounts of naturally occurring nicotine. The any-source nicotine amendment was enacted on 15 March 2022 and took effect on 14 April 2022; it is not a new 2026 requirement. U01
An empty device or a zero-nicotine liquid is not automatically outside tobacco regulation. FDA’s guidance explains that components and parts can fall within the definition whether or not they contain nicotine or are made or derived from tobacco. The regulatory component-or-part test concerns software or materials intended or reasonably expected to affect a tobacco product’s performance, composition, constituents or characteristics, or to be used with or for its human consumption; it excludes a defined accessory. FDA identifies e-liquids, atomizers, tanks, certain batteries and programmable software as examples of regulated ENDS components and parts. U15 U03 U05R
“Accessory” is therefore a defined category, not a synonym for something sold separately. Under section 1100.3, it must be intended or reasonably expected to be used with or for human consumption of a tobacco product, contain no tobacco and not be made or derived from tobacco. It must also meet the specified functional conditions: either no intended or reasonably expected effect on the product’s listed characteristics, or the narrow alternatives for solely controlling stored-product moisture or temperature, or solely providing external heat to start—but not maintain—combustion. Section 1100.2 excludes accessories of the other tobacco products it deems subject to Chapter IX; it separately subjects products containing non-tobacco-derived nicotine to that chapter. The deeming exception should not be confused with an exclusion of every accessory from the statutory definition. U03 U12
Intended use is another boundary. The statute excludes articles that meet its drug, device or combination-product definitions from “tobacco product.” For products made or derived from tobacco, section 1100.5 specifies intended uses such as treating nicotine addiction, smoking cessation, preventing relapse or relieving withdrawal symptoms. Its separate structure-or-function branch concerns effects different from nicotine-related effects commonly and legally claimed for cigarettes and smokeless tobacco before 21 March 2000. These are alternative branches, not a rule that every nicotine-related statement automatically makes a product a drug. U01 U04
FDA’s ENDS page says products marketed for therapeutic purposes, such as helping people quit smoking, are regulated by its Center for Drug Evaluation and Research. For a business, the practical point is to examine intended use and claims before choosing a tobacco registration route. Neither a nicotine-origin label nor a tobacco registration record establishes that a therapeutic claim is acceptable. The wording of section 1100.5 specifically addresses products made or derived from tobacco; it should not be used as a stand-alone classification answer for every synthetic-nicotine product. The statutory exclusions still matter. This guide does not determine which drug, device or combination-product route a particular product would require. U05R U01 U04
Map the actual activities and establishments
Section 905 of the Food, Drug, and Cosmetic Act, codified at 21 U.S.C. §387e, places registration duties on people who own or operate an establishment in any State engaged in manufacturing, preparing, compounding or processing tobacco products. Its definition expressly includes repackaging or changing a package’s container, wrapper or labeling in furtherance of distribution from the original manufacturer to the person making final delivery or sale to the consumer. FDA’s finished-product enforcement policy, discussed below, is distinct from this statutory wording. U02
| Business situation | What the sources establish—and the boundary to retain |
|---|---|
| A person owns or operates a domestic establishment that mixes, processes, repackages or relabels tobacco products | Assess registration and product listing against the actual activities and the statutory test, not just the business’s trading description. Repackaging and relabeling can fall within the manufacturing definition; the distribution condition in that definition matters. U02 U06 |
| A vape shop also mixes nicotine-containing e-liquids or creates or modifies ENDS | FDA says it may be a manufacturer, and some vape shops have both manufacturer and retailer responsibilities. This is not a conclusion that every shop is a manufacturer or that a retail role displaces manufacturing duties. U05R |
| An importer of finished tobacco products does not own or operate a domestic establishment engaged in manufacture, preparation, compounding or processing | FDA’s importing page says such importers are not required to register an establishment or provide product listings, but must meet all other applicable tobacco-product manufacturer requirements. Keep the finished-product context and domestic-establishment condition; “importer” alone is not an exemption. U07 |
| An existing registrant adds another qualifying establishment | The statute requires immediate registration of the additional establishment when the person begins the specified activities there. A business-level record is not a reason to omit an additional qualifying site. U02 |
FDA’s registration guidance describes an establishment as a place of business under one ownership at one general physical location. It describes an owner by an ownership interest in the establishment and an operator by management authority. Its domestic-establishment definition includes establishments in US States, Territories or possessions. Those distinctions help identify the relevant people and sites; they are not a finding that a brand name or an importer’s mailing address answers the statutory test. U15
Separate the first registration from recurring updates
For a person within the statutory registration requirement, the timing is not simply “wait until year-end”:
- First engaging in the covered activities: section 905(c) requires immediate registration. Section 905(i)(1) requires the product list at registration; FDA’s registration page likewise describes immediate registration and listing for new establishments. U02 U06
- Annual registration: section 905(b) sets 31 December as the annual deadline. U02
- Product-listing changes: the statute calls for reports during June and December covering new, discontinued or resumed products and material changes to previously submitted information. FDA’s current registration page gives deadlines of 30 June and 31 December and says only establishments making the specified changes need to update their listings; previously submitted information should not simply be resubmitted unchanged. Annual registration and a conditional listing update are different tasks. U02 U06
There is also an important distinction between the statutory requirement and enforcement policy. FDA’s March 2023 nonbinding registration guidance says it intends to enforce registration and listing for finished tobacco products only, excluding accessories, and does not at that time intend to enforce those requirements for products sold or distributed solely for further manufacturing. That is the agency’s stated compliance policy, not a statutory exemption or a product authorization. U15
Under that guidance, a finished tobacco product includes components and parts sealed in final packaging intended for consumer use. Separately sold components can therefore be finished products: the examples include e-cigarette batteries and e-liquids sold to consumers on their own or in kits. “Component” does not by itself place an item within the further-manufacturing policy. U15
The September 2026 form change is relevant to this year’s filing
FDA’s 29 September announcement says it launched a redesigned Form FDA 3741 on 28 September 2026, covering all regulated tobacco-product categories, including e-cigarettes. The previous versions of Forms 3741 and 3741a were retired. Existing submissions remain in TRLM NG, and the announcement says businesses do not need to resubmit their entire registration solely because of the redesign. The downloaded form is marked 09/26. This is a change to the submission tool, not evidence of a new product authorization. U13 U16
FDA strongly encourages electronic submission through TRLM NG, but its registration page also describes a paper route for manufacturers unable to submit electronically. It says submissions must be received by FDA no later than the applicable 30 June or 31 December deadline. Businesses preparing the year-end submission should use the updated instructions rather than assume an older form or a mailing date is sufficient. U06
What a registration or listing record does not establish
The first page of the revised form expressly says registration or listing does not denote FDA authorization to market tobacco products in the United States. Section 905(i)(1)(A) itself asks for a reference to marketing authority for the products to which that provision applies. For new tobacco products, section 910, codified at 21 U.S.C. §387j, sets a separate premarket framework with specified routes and exceptions. A registration receipt is not a substitute for evidence of the marketing status applicable to the particular product. This does not mean every tobacco product follows an identical PMTA route. U16 U02 U09
Foreign establishments are a separate question from the importer scenario above. Section 905(h) addresses foreign registration under regulations promulgated by FDA. On 29 June 2026, FDA published a proposal to extend registration and listing to foreign establishments and prescribe procedures for domestic and foreign establishments: 91 FR 39168, document 2026-13047, RIN 0910-AH59. That publication is a proposed rule, not a final rule or its effective date. This guide reports the proposal as a dated event; it does not determine a foreign facility’s current registration obligations across any later implementing instruments. Nor does the proposal establish an exemption from other applicable US requirements. U02 U17
Federal registration also does not settle every destination’s rules. Section 916, codified at 21 U.S.C. §387p, preserves specified federal, state, local and tribal authority, subject to its preemption provisions. It restricts different or additional state and local requirements in listed fields, including registration, while expressly excepting fields such as sale and distribution from that restriction. State, tribal and local taxation is expressly unaffected. The wording and the jurisdiction matter; these clauses are not a finding that a particular state, locality or tribal destination permits a sale. No destination-specific rule is assessed here. U08
Questions to settle before changing operations
Use the distinctions above to ask for different evidence rather than one all-purpose “FDA certificate”:
- Product: What are the ingredients, intended use, claims, functional role and consumer packaging of the exact item?
- Activity and location: Who owns or operates each establishment, and what mixing, manufacturing, processing, repackaging or relabeling actually happens there?
- Registration and listing: Is this a first registration, an additional establishment, the annual renewal, or a reportable listing change—and which source supports the timing?
- Separate permissions: What evidence addresses that product’s marketing status, any therapeutic classification issue, and the particular destination’s requirements?
These are an evidence-gathering approach, not a guarantee that completing a list clears a product or business for sale.
Reporting scope: official sources were checked on 19 November 2026. The cited US Code displays incorporate laws through Public Law 119-142 of 10 November 2026. The cited eCFR pages display Title 21 as up to date through 17 November 2026 and are not an official legal edition of the CFR. Source-specific publication and update dates remain distinct from the checking date. This article does not cover drug/device applications, detailed import or PACT procedures, individual product orders, litigation outcomes, or a state-by-state or tribal-law survey.
Official sources
- U01 — 21 U.S.C. §321: definitions and the 2022 amendment’s effective-date note.
- U02 — 21 U.S.C. §387e: establishment registration and product listing.
- U03 — 21 CFR §1100.3: accessory, component and part definitions.
- U04 — 21 CFR §1100.5: exclusion from tobacco regulation.
- U05R — FDA: E-Cigarettes, Vapes, and other ENDS; page current 17 August 2026.
- U06 — FDA: Tobacco Product Establishment Registration and Product Listing; page current 29 September 2026.
- U07 — FDA: Importing and Exporting; page current 3 January 2025.
- U08 — 21 U.S.C. §387p: preservation of state and local authority and preemption.
- U09 — 21 U.S.C. §387j: review of certain tobacco products.
- U12 — 21 CFR §1100.2: requirements applicable to tobacco products.
- U13 — FDA: redesigned registration and listing form announcement, 29 September 2026.
- U15 — FDA: Registration and Product Listing for Owners and Operators of Domestic Tobacco Product Establishments; March 2023 nonbinding guidance, especially sections III–IV.
- U16 — Form FDA 3741, revision 09/26; disclaimer on page 1.
- U17 — Establishment Registration and Product Listing for Tobacco Products; proposed rule, 29 June 2026, 91 FR 39168–39203.